Market Intelligence, Clinical Progress, and High-Purity Reagents for T-Cell Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD7 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD7 Products |
| Gene Delivery | CD7 Full-Length ORF Lentivirus Premade particles for stable cell line construction. Preserve native conformation for flow cytometry & internalization assays. |
View CD7 Products |
| Benchmark Ab | Anti-CD7 Recombinant Antibody (Biosimilar) Sequence-matched positive control for binding & functional assays. (Clinical sequence biosimilar available, e.g., AZD0486 sequence) |
View CD7 Products |
| Validator | CD7 siRNA Validation Set For knockdown specificity confirmation in target engagement studies. |
View CD7 Products |
| Related Target A | CD3E T-Cell co-receptor for CD7×CD3 bispecific & CAR-T activation design. |
View CD3E Products |
| Related Target B | CD5 Co-expressed in T-cell lymphomas; dual-targeting CAR-T to prevent antigen escape. |
View CD5 Products |
| Related Target C | TRAC TCR alpha constant region; gene-editing target for allogeneic CD7 effector cell engineering. |
View TRAC Products |
Critical Assay Requirements & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Preclinical Safety (Human/Mouse/Cyno) | Human/Mouse/Cyno ortholog CD7 ECD proteins available; >95% purity; Endotoxin <1 EU/µg for in vivo dosing. |
| Fratricide & On-target T-cell Toxicity (CAR-T) | Lentivirus for stable CD7 Knock-out / Knock-in cell lines; siRNA set for transient target suppression controls. |
| Internalization & ADC Payload Delivery | High-purity CD7 ECD-Fc (native glycosylation) and full-length lentivirus enable pH-dependent & direct internalization assays. |
| Epitope Specificity & Off-target Screening | Sequence-verified homolog panel (CD3E, CD5, TRAC) for stringent counter-screening by SPR/BLI. |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Biosimilars) with strictly verified sequences included. |
Live CD7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD7 therapeutics is intensifying, with major players shifting focus from traditional chemotherapy to CAR-T, ADC, and bispecific modalities. Because CD7 is highly expressed in T-ALL, PTCL, and a subset of AML, it is a prime target for hematological malignancies. However, shared expression on normal T cells and NK cells causes significant fratricide during CAR-T manufacturing. As first-generation therapies reach the clinic (Phase I/II), the next wave of R&D is targeting fratricide-resistant engineering (CD7-knockout CAR-T via CRISPR, intracellular retention strategies), masked antibody formats, and combination regimens to mitigate on-target T-cell aplasia. Allogeneic CAR-T cells with dual gene editing (CD7 and TRAC knockout) are advancing rapidly, while ADCs leverage CD7's rapid internalization for payload delivery. Emerging bispecific antibodies (CD7×CD3) aim to redirect endogenous T cells but must balance efficacy with CRS risk.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T (Allogeneic / Gene-Edited) | Wugen, IASO Bio, Gracell (AstraZeneca), PersonGen, Hebei Senlang, Nanjing Legend | T-ALL, AML, PTCL, T-LBL | Fratricide Evasion & T-cell Activation (Need Lentivirus for CD7/TRAC KO cell lines, siRNA for target validation) |
| ADC | AstraZeneca (AZD0486), BioNTech, Multiple Preclinical Biopharma | Relapsed/Refractory T-ALL, AML, Sézary Syndrome | Internalization Efficiency (Need high-purity ECD-Fc with native glycosylation for binding and kinetic assays) |
| Bispecific (CD7×CD3) | Emerging Immuno-Oncology Developers | Peripheral T-Cell Lymphoma, Autoimmune (T-cell depletion) | T-Cell Engagement & Cross-linking (Need cross-reactive anti-CD3E & anti-CD7 benchmark Abs, heterodimer validation) |